Mavacamten

5 trials CCardiology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

4 Completed trials

3 Sponsors

17 Countries

Phase III

Phase III/IV

Phase IV

Phase III: 3 Phase III/IV: 1 Phase IV: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Hypertrophic cardiomyopathy 2 Non-obstructive cardiomyopathy 1

Sponsors using this IMP

Myokardia Inc. 3 Bristol-Myers Squibb Services Unlimited Company 1 Region Skane 1

All trials

5 total

Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Pending

2025-524722-17-00 Phase IV 1 country Region Skane
A Study of Mavacamten in Adolescent Participants with Symptomatic Obstructive Hypertrophic Cardiomyopathy Ended

2023-505650-17-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Phase III 13 countries Myokardia Inc.
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY… Ended

2022-502858-14-00 Phase III 10 countries Myokardia Inc.
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 Phase III/IV 11 countries Myokardia Inc.

Showing 1–5 of 5 trials

← All drugs A–Z